David A. Siegel Puma Biotechnology, Inc. Call Options Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding PBYI
# of Institutions
99Shares Held
29.5MCall Options Held
842KPut Options Held
32.2K-
Vanguard Group Inc Valley Forge, PA3.49MShares$10.3 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.17MShares$9.34 Million0.01% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA2.82MShares$8.31 Million0.78% of portfolio
-
Acadian Asset Management LLC Boston, MA1.96MShares$5.77 Million0.04% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.73MShares$5.1 Million0.01% of portfolio
About PUMA BIOTECHNOLOGY, INC.
- Ticker PBYI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,556,000
- Market Cap $134M
- Description
- Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...